Ask AI
Obesity Management During Reproductive Years
Clinical Queries: Expert Insights to Improve Obesity Management During Reproductive Years 

Released: January 20, 2026

Activity

Progress
1
Course Completed

  1. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update. Endocr Pract. 2025;31:1351-1394.
  2. Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10:396-408.
  3. Barrett TS, Hafermann JO, Richards S, et al. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg. 2025;160:1232-1239.
  4. Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertil Steril. 2021;116:1266-1285. 
  5. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36. 
  6. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc.; 2025.
  7. Tirzepatide [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2025.
  8. Abdalla MA, Deshmukh H, Atkin S, et al. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021;12:2042018821989238.
  9. Tirzepatide [product information]. Firenze, Italy: Eli Lilly Italia S.p.A.; 2024.
  10. Tirzepatide [product monograph]. Toronto, Canada: Eli Lilly Canada Inc.; 2025.
  11. Wu H, Yang W, Guo T, et al. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Med. 2025;23:398.

 

Continue the activity for another interactive case.